December 2025 – Page 3

Moderna Lands CEPI as New Backer for Its Pandemic Flu (H5 Bird Flu) Program

1 month ago talkbio0Tagged CEPI, coalition, Epidemic Preparedness Innovations, Funding, H5 bird flu, Moderna, mRNA Vaccine, pandemic influenza, pandemic preparedness, Phase 3 trial, Vaccine Development

Moderna; CEPI; Coalition for Epidemic Preparedness Innovations; pandemic influenza; H5 bird flu; mRNA vaccine; Phase 3 trial; pandemic preparedness; vaccine development; funding

Endpoints News Topics at 2026 JPM Healthcare Conference: CEOs, Investors, China, and Beyond

1 month ago talkbio0Tagged AI healthcare, Biopharma, CEOs, Endpoints, investors, JPM Healthcare Conference, News [Publication Type], Private Equity

JPM Healthcare Conference; Endpoints News; CEOs; investors; AI healthcare; biopharma; private equity

Coloplast announces changes to Executive Leadership Team

1 month ago talkbio0Tagged Administration occupational activities, Anthropological Culture, Changing, coloplast, ELT, Executive Leadership Team, Interventional Urology, Johns, Kevin Hardage, Leadership, Persons, Transition Mutation

Coloplast; Executive Leadership Team; ELT changes; Interventional Urology; People & Culture; Kevin Hardage; Tommy Johns; leadership transition; management changes

Quantori and Expert Systems Partner to Accelerate Drug Discovery with Foundational Predictive AI Models

1 month ago talkbio0Tagged AI models, Dosage Forms, Drug Discovery, Expert Systems, Q-Scientist, Quantori, R&D

Quantori; Expert Systems; drug discovery; AI models; Q-Scientist; pharmaceutical R&D

Ipsen’s Fidrisertib Fails Primary Endpoint in Pivotal Phase II FALKON Trial for Rare Bone Disease FOP

1 month ago talkbio0Tagged Clinical Trials, FALKON, Fibrodysplasia Ossificans Progressiva, fidrisertib, Heterotopic Ossification, Ipsen, Phase II Failure

Ipsen; fidrisertib; FALKON trial; FOP; Phase II failure; heterotopic ossification

Lilly seeks rapid FDA approval for oral GLP-1 orforglipron after positive obesity “switching” study

1 month ago talkbio0Tagged Approved, Clinical Trials, Eli, Glucagon-Like Peptide 1, injectable incretins, national priority review voucher, Obesity, Oral cavity, orforglipron, Phase 3 trial, United States Food and Drug Administration, Wegovy, weight maintenance, Zepbound

Eli Lilly; orforglipron; oral GLP-1; FDA approval; national priority review voucher; ATTAIN-MAINTAIN trial; obesity treatment; weight maintenance; Zepbound; Wegovy; injectable incretins; Phase 3 trial

GSK strikes RNA-based neuro and kidney disease collaboration with CAMP4 Therapeutics

1 month ago talkbio0Tagged Antisense Oligonucleotides, Antistreptolysin O, CAMP4, Collaboration, gene upregulation, Kidney Diseases, LRPAP1 gene, milestone payments, Neurodegenerative Disorders, Platform, regulatory RNA, RNA therapeutics, royalties, SmithKline Beecham

GSK; CAMP4 Therapeutics; RNA therapeutics; regulatory RNA; antisense oligonucleotides; ASO; RAP Platform; neurodegenerative diseases; kidney disease; renal disease; gene upregulation; biotech collaboration; licensing deal; milestone payments; tiered royalties

Exclusive: Compounding giant Empower Pharmacy cuts hundreds of staff, stops New Jersey operations

1 month ago talkbio0Tagged compounding pharmacy, East Windsor facility, Empower Pharmacy, Facility (object), Glucagon-Like Peptide 1, Inspection (procedure), layoffs, manufacturing shutdown, New Jersey operations, Outsourcing, Qualitative form, United States Food and Drug Administration, Workforce reduction

Empower Pharmacy; compounding pharmacy; layoffs; job cuts; New Jersey operations; East Windsor facility; manufacturing shutdown; outsourcing facility; FDA inspection; Form 483; compounded GLP-1 drugs; workforce reduction

No public results for “Take the Biopharma Sentiment Index” Q1 2026 yet

1 month ago talkbio0Tagged Attitude, Biological Science Disciplines, Biopharma, biopharma executives, Biopharma Sentiment Index, geopolitical risk, M&A activity, Q1 2026, Sentiment, Surveys

Biopharma Sentiment Index; Q1 2026; biopharma executives; life sciences sentiment; 2026 outlook; M&A activity; AI in biopharma; geopolitical risk; survey data

Biopharma’s Winners and Losers of 2025 – Endpoints News recap

1 month ago talkbio0Tagged 2025, Biopharma, Endpoints, Kyle LaHucik, Losers, movers, News [Publication Type], Pharma, Post-Hoc Live, Review [Publication Type], winners

Endpoints News; winners and losers; 2025; biopharma; Post-Hoc Live; Kyle LaHucik; year in review; biotech; pharma; stock movers